The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (saquinavir)

Pharmaceutical Research

Volumn 15, Issue 3, 1998, Pages 417-422

  Kenyon, C J ^a   Brown, F ^b   McClelland, G R ^b   Wilding, I R ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Food effects; Gastrointestinal tract; Pharmacoscintigraphy; Protease inhibitor; Saquinavir

Indexed keywords

GELATIN; PROTEINASE INHIBITOR; SAMARIUM 153; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MIXTURE; FEMALE; FOOD INTAKE; GASTROINTESTINAL TRANSIT; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; ISOTOPE LABELING; MALE; MICROCAPSULE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STOMACH CONTENT; STOMACH EMPTYING;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; COLON; CROSS-OVER STUDIES; EATING; FEMALE; FOOD-DRUG INTERACTIONS; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; HIV PROTEASE INHIBITORS; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; SAQUINAVIR; TECHNETIUM;

EID: 0031946801     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011972230829     Document Type: Article

References (21)

1. R. A. Kramer, M. D. Schaber, A. M. Skala et al. Science 231:1580 (1986).
2. J. C. Craig, C. Greif, J. S. Mills et al. Antivir. Chem. Chemother. 2:188-186 (1991).
3. R. Pauwels, K. Andries, J. Desmyter et al. Nature 343:470 (1996).
4. G. Moyle, Exp. Opin. Invest. Drugs 5:155-167(1996).
5. V. S. Kitchen, C. Skinner, K. Ariyoshi et al. Lancet 345:952-955 (1995).
6. S. S. Davis, J. G. Hardy, S. P. Newman, and I. R. Wilding. Eur. J. Nuci Med. 19:971-986 (1992).
7. J. N. Hunt and I. MacDonald. J. Physiol. 126:459-474 (1954).
8. I. R. Wilding, S. S. Davis, K. P. Steed, R. A. Sparrow, J. Westrup, and J. M. Hempenstall. Int. J. Pharm. 101:263-268 (1994).
9. C. F. Code and J. A. Martlett. J. Physiol. 246:289-309 (1975).
10. S. S. Davis, J. G. Hardy, and J. W. Fara. Gut. 27:886-892 (1986).
11. J. M. C. Price, S. S. Davis, R. A. Sparrow, and I. R. Wilding. Pharm. Res. 10:722-726 (1993).
12. J. N. Hunt and D. F. Stubbs. J. Physiol. 245:209-225 (1975).
13. G. Moyle and B. Gazzard. Drugs 51(5):701-712 (1996).
14. J. A. Ganley, J. McEwan, R. T. Calvert, and M. C. J. Barker. J. Pharm. Pharmacol. 36:734-739 (1984).
15. J. B. Dressman, P. Bass, W. A. Ritschel, D. R. Friend, A. Rubinstein, and E. Ziv J. Pharm. Sci. 82(9):857-872 (1993).
16. L. Williams, D. P. Hill, J. A. Davis, and D. T. Lowenthal. European Journal of Drug Metabolism and Pharmacokinetics 21(3):201-211 (1996).
17. M. G. Sarr, K. A. Kelly, and S. F. Philips. Am. J. Physiol. 239:G167-172 (1980).
18. N. F. LaRusso, M. G. Korman, N. E. Hoffman, and A. F. Huffman. New England Journal of Medicine 291:689-692 (1974).
19. R. Aldini, A. Roda, M. Montagnani, and E. Roda. Italian Journal of Gastroenterology 27(3):141-144 (1995).
20. Anonymous. Scrip. 2216:28 (21 March 1997).
21. J. M Schapiro, M. A. Winters, M. J. Kozal et al. 35th Interscience Conference on Antimicrobial agents and Chemotherapy: 1995 Sep 17-20; San Francisco.